Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gusperimus in Relapsing Granulomatosis With Polyangiitis
NCT01446211Phase 3Terminated
- Sponsor
- Nordic Pharma
- Start
- Nov 2011
- Primary completion
- Nov 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of deoxyspergualin in granulomatosis with polyangiitis (GPA) (2 arms), sponsored by Nordic Pharma. Primary endpoint: Response rate at 52 weeks. Started Nov 2011; status: terminated.
02
Drugs
deoxyspergualin
03
Conditions
granulomatosis with polyangiitis (GPA)
Beyond the preview
Go deeper on NCT01446211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01446211.